Skip to main content

Mesothelioma Clinical Trials

Review the mesothelioma clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-49 of 49

CD70 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells and Lymphodepleting Chemotherapy for the Treatment of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pembrolizumab in Combination with Chemotherapy and Image-Guided Surgery for the Treatment of Resectable Pleural Malignant Mesothelioma (MPM)
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Y-NM600 in Combination with Immune Checkpoint Inhibitors in Treating Patients with Metastatic Cancer
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
Clinical Trial of PM54 in Advanced Solid Tumors Patients.
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Surgical Procedure (Partial Pleurectomy and Decortication) for the Treatment of Borderline Resectable and Unresectable Pleural Mesothelioma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Status: Active
Location: See ClinicalTrials.gov
ALG.APV-527 First-in-human Study
Status: Active
Location: See ClinicalTrials.gov
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Status: Temporarily Closed to Accrual
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Vudalimab for the Treatment of Advanced Rare Cancers
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Atezolizumab and Bevacizumab in Treating Patients with Rare Solid Tumors
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Paclitaxel-Loaded Tumor Penetrating Microparticles for the Treatment of Peritoneal Carcinomatosis
Status: Temporarily Closed to Accrual
Location: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa
Genetic Testing on Blood Samples for Treatment Suggestions in Patients with Advanced or Metastatic Cancer
Status: Active
Location: 3 locations
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Using E-Nose Technology to Measure Response to Treatment in Patients with Malignant Pleural Mesothelioma
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Pleural Tissue Samples Collection in Determining the Stage and Prognosis of Patients with Mesothelioma
Status: Active
Location: Brigham and Women's Hospital, Boston, Massachusetts
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Status: Active
Location: See ClinicalTrials.gov
Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Evaluation of Tissue and Blood for Patients Undergoing Surgery, Biopsy or Endoscopy for Gastrointestinal Cancers
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
ERAS® Guidelines Validation of CRS With or Without HIPEC
Status: Active
Location: See ClinicalTrials.gov